Clinical trials: Adenovirus Infections
HIV Infections
Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults
The purpose of this study is to determine the safety of and immune response to an experimental HIV vaccine in HIV uninfected individuals.
- Trial name
- NCT00119873
- Testing
- VRC-HIVADV014-00-VP
- Where
- 3 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
This is a phase 2/3, multicenter, randomized, placebo-controlled, observer-blind study assessing the safety, tolerability, immunogenicity, and efficacy of prophylactic hAd5-S-Fusion+N-ETSD against COVID-19.
- Trial name
- NCT06022224
- Testing
- hAd5-S-Fusion+N-ETSD
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Herpes Zoster
A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years
This is a randomized, observer blind and controlled study. Participants in low-dose and high-dose IM group will be randomized in a ratio of 2:1 to receive either the investigational product or the control.
- Trial name
- NCT05991427
- Testing
- Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV), Zoster Vaccine Recombinant, Adjuvanted (Shingrix), ChAdOx1-VZV
- Where
- Canada
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Covid19
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults
This is a phase 1b, open-label study in adult healthy participants. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of the hAd5-S-Fusion+N-ETSD vaccine and select a dose for future studies.
- Trial name
- NCT04710303
- Testing
- hAd5-S-Fusion+N-ETSD vaccine
- Where
- South Africa
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
COVID-19
Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults
The 2019 novel-coronavirus (2019-nCov) is the cause of a cluster of unexplained pneumonia that started in Hubei province in China.
- Trial name
- CTCOVID-19 (NCT04313127)
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Tuberculosis
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
This is a phase 1 study, in healthy volunteers who have previously been immunized with bacilli Calmette Guerin (BCG), to evaluate the safety and immune responses that develop in the blood and lungs following the administration by…
- Trial name
- NCT02337270
- Testing
- Ad5Ag85A
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- McMaster University
Healthy
A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02313077
- Testing
- MVA-BN-filo, Ad26. ZEBOV
- Where
- United Kingdom
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Covid19
Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV
A randomized, double-blind, placebo -controlled, phase IIb clinical trial to evaluate the efficacy, safety and immunogenicity of one or two doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18…
- Trial name
- COVID-19 (NCT05005156)
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
- Where
- 4 sites in Argentina
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Fundación Huésped
Ebola Virus Disease, Hemorrhagic Fever
Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)
Ebola virus causes an infection known as Ebola virus disease (EVD). This it is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever.
- Trial name
- NCT02368119
- Testing
- VRC-EBOADC069-00-vp, MVA-EbolaZ
- Where
- Mali
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
HIV Infections
Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults
The purpose of this study is to evaluate the safety and immune response of an adenovirus-based HIV-1 vaccine regimen that includes two vaccines given at different time points in HIV-uninfected adults.
- Trial name
- NCT01095224
- Testing
- rAd35 Env A, rAd5 Env A, rAd5 Env B
- Where
- 8 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention
The purpose of the study is to assess safety and immunogenicity of heterologous booster vaccine containing combination of AZD1222 and rAd26-S (one of components of Gam-COVID-Vac vaccine) in adult subjects aged ≥ 18 years old to…
- Trial name
- NCT04686773
- Testing
- AZD1222, rAd26-S
- Where
- Azerbaijan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Influenza A Subtype H5N1 Infection
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
The purpose of this study is to test the recombinant vaccine for safety and immunogenicity in healthy adults volunteers. Single dose, intranasally administered vaccine using an adenovirus-recombinant vector has provided a safe…
- Trial name
- NCT00755703
- Testing
- Pandemic Influenza Vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
COVID-19
Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)
This phase III clinical trial is an endpoint-driven randomized, double-blind, parallel-controlled, multicenter clinical trial, and around 13,000 subjects aged 18 years and above who have previously received 1 dose of…
- Trial name
- NCT05124561
- Testing
- Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
- Volunteers
- healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization
Sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses Inactivated COVID-19 Vaccine
COVID-19 is a novel coronavirus infection caused by respiratory droplets and contact transmission. With the spread of the epidemic, it has become a serious threat to global public health.
- Trial name
- NCT05373030
- Testing
- Recombinant adenovirus type-5-vectored COVID-19 vaccine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Healthy Adult Volunteers
Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination
The investigators conduct a prospective analysis to compare homologous and heterologous adenovirus vector ChAdOx1-nCov-19 (Astra-Zeneca) or SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine inoculation.
- Trial name
- NCT05074368
- Testing
- ChAdOx1-nCov-19 (Astra-Zeneca), SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
- Where
- Taiwan
- Volunteers
- 499 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Intracerebral Hemorrhage
Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study
This study is determining the clinical outcomes, based on neurological testing, for the parafascicular minimally invasive clot evacuation technique. We will collect data from the time of surgery up until 90 days post procedure.
- Trial name
- MISPACE (NCT01971359)
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- OSF Healthcare System
COVID-19
A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)
This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in healthy adults above 18 years of age. This clinical trial is designed to evaluate the immunogenicity and safety of Ad5-nCoV which encodes for…
- Trial name
- CTII-nCoV (NCT04341389)
- Testing
- Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)
- Where
- China
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China
Malaria
Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria
The purpose of this study is to test the safety and effectiveness of a new malaria vaccine, the DNA-Ad vaccine. The study is specifically looking at a vaccine regimen against Plasmodium falciparum, the most deadly form of malaria.
- Trial name
- DNA-Ad (NCT00870987)
- Testing
- DNA vaccine prime, adenovirus type 5 vaccine boost
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Covid19
Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus
Randomized, double-blind (blinded for the trial subject and the study physician), placebo controlled, multi-center clinical trial in parallel assignment of efficacy, immunogenicity, and safety of the Gam-COVID-Vac combined vector…
- Trial name
- NCT04564716
- Testing
- Gam-COVID-Vac
- Where
- 8 sites in Belarus
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
COVID-19
Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults
This is a multicenter, US-only, phase 1, open-label, dose escalation, non-randomized study of the safety, tolerability, and immunogenicity of investigational ChAd and SAM SARS-CoV-2 vaccines in healthy adult subjects.
- Trial name
- NCT04776317
- Testing
- ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S
- Where
- 4 sites in United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)